Success Story: Clinical Medicine Expert Secures I-140 NIW Approval for Research Advancing Pediatric Cancer Care
Client’s Testimonial:
"Thank you again for your outstanding assistance and support throughout this process. I truly appreciate all your hard work and guidance.”
On June 19th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Pediatrics Resident in the Field of Clinical Medicine (Approval Notice).
General Field: Clinical Medicine
Position at the Time of Case Filing: Pediatrics Resident
Country of Origin: Iraq
State of Residence at the Time of Filing: Texas
Approval Notice Date: June 19th, 2026
Processing Time: 3 months, 25 days (Premium Processing Upgrade Requested)
Case Summary:
We are pleased to share that North America Immigration Law Group successfully secured an I-140 National Interest Waiver approval for a client in the field of clinical medicine. The client holds a Ph.D. in medical sciences and is currently employed as a pediatric resident, continuing work that connects translational cancer research with clinical pediatric care.
The client’s proposed endeavor is to continue developing and advancing translational, mechanism-driven approaches for creating targeted and less toxic therapies for pediatric cancers. His work integrates molecular oncology with clinical pediatric practice to improve therapeutic precision, reduce treatment-related toxicity, and strengthen national pediatric cancer outcomes and child health at scale.
In preparing the petition, we demonstrated that the client’s research carries substantial merit and national importance because it addresses the urgent need for more precise pediatric cancer therapies and improved child health outcomes. We also emphasized that the client’s work is not limited to one employer or institution, since his findings have been shared through scholarly research and relied upon by other researchers working to advance precision oncology and targeted therapeutic development.
The client’s record included:
- 10 peer-reviewed journal articles, including 1 first-authored article
- 2 preprints
- 4 abstracts, including 1 first-authored abstract
- 1 book chapter
- 499 citations to his published body of work
These metrics were presented not as numbers alone, but as evidence of how the field has responded to the client’s research. The citation record helped show that other researchers have relied on his findings in their own studies, while his publication history demonstrated sustained engagement with clinically relevant questions in oncology, molecular medicine, and therapeutic development.
The petition was supported by 4 recommendation letters from experts in the field. These letters helped explain how the client’s research has contributed to mechanism-driven cancer therapy, biomarker evaluation, and translational approaches that may support more precise and less toxic treatment strategies.
“With his expertise, [Client] continues to make critical accomplishments in both cancer biology research and pediatric healthcare progress.”
This approval reflects the strength of a carefully prepared petition that connected the client’s credentials, research record, and future plans to a nationally important medical endeavor. By showing how his work advances pediatric cancer research, supports therapeutic precision, and contributes to broader child health outcomes, we established that the client is well-positioned to continue making meaningful contributions in clinical medicine.
We congratulate the client on this I-140 NIW approval and wish him continued success in his important work.